放射性核素治疗转移性去势抵抗性前列腺癌新进展

Adionuclide therapy for metastatic castration-resistant prostate cancer:New advances

前列腺癌(PCa)是男性泌尿生殖系统最常见的肿瘤之一,在全球男性恶性肿瘤中排名第二;年龄是PCa的主要危险因素,人口的日益老龄化导致全球PCa发病率逐渐升高。雄激素剥夺治疗目前是PCa的一线治疗方法,但随着疾病的进展,许多PCa患者会对雄激素剥夺治疗产生耐药性,并发展为去势抵抗性前列腺癌(CRPC);这标志着PCa向激素难治性状态的转变,与预后不良相关。转移性去势抵抗性前列腺癌(mCRPC)是该疾病的终末期,也是死亡的主要原因。尽管mCRPC的治疗取得了许多新的进展,但其预后仍然较差。对于mCRPC患者,化疗和雄激素阻断药物的经典治疗方案的生存获益有限,放射性核素治疗凭借其独特的优势已成为mCRPC患者的的一种新型治疗选择。本文主要综述了近些年来放射性核素治疗mCRPC的最新研究进展。

Prostate cancer(PCa)is one of the most common tumors of the male urogenital system,ranking the second among male malignancies worldwide.Age is a major risk factor for PCa,and population aging leads to an increasing incidence of the malignancy.Androgen-deprivation therapy(ADT)is currently the first-line treatment of PCa,but with the advance of the tumor,many of the patients become resistant to ADT and develop castration-resistant prostate cancer(CRPC),which marks a transition of PCa to a hormone-refractory state associated with a poor prognosis.Metastatic CRPC(mCRPC)is the terminal stage of the disease and a leading cause of death.Despite many new advances in the treatment of mCRPC,its prognosis remains poor.For patients with mCRPC,classical treatment options with chemotherapy and androgen-blocking agents have limited survival benefit,and radionuclide therapy has become a novel therapeutic option for mCRPC.This paper focuses on the development of the radionuclide therapy for mCRPC in recent years.